API | bicifadine

bicifadine Report issue

Small molecule Experimental

AACT DrugBank MeSH PubChem

Active Ingredient History

NOW

Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth. ^Wikipedia

Chemistry

SMILES: Cc1ccc(C23CNCC2C3)cc1
InChIKey: OFYVIGTWSQPCLF-UHFFFAOYSA-N
Mol. Mass: 173.26
ALogP: 1.86 Partition coefficient
ChEMBL Molecule:
bicifadine

More Chemistry

Pharmacology

Mechanisms of Action:
- Sodium-dependent serotonin transporter (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bicifadine | bicifadine hydrochloride

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Back Pain (Phase 3)

Chronic Pain (Phase 2)

Depression ()

Diabetes Mellitus (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue